Lysosomal quality control: molecular mechanisms and therapeutic implications

H Yang, JX Tan - Trends in Cell Biology, 2023 - cell.com
Lysosomes are essential catabolic organelles with an acidic lumen and dozens of hydrolytic
enzymes. The detrimental consequences of lysosomal leakage have been well known since …

[HTML][HTML] Signal pathways in the treatment of Alzheimer's disease with traditional Chinese medicine

MR Ding, YJ Qu, B Hu, HM An - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Aim of the review This study aimed to reveal the classical signal pathways and important
potential targets of traditional Chinese medicine (TCM) for treating Alzheimer's disease (AD) …

[HTML][HTML] A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and …

J Song, GN He, L Dai - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Celastrol, triptolide and triptonide are the most significant active ingredients of Tripterygium
wilfordii Hook F (TWHF). In 2007, the 'Cell'journal ranked celastrol, triptolide, artemisinin …

Transcriptional regulation of autophagy and its implications in human disease

Y Lei, DJ Klionsky - Cell Death & Differentiation, 2023 - nature.com
Macroautophagy/autophagy is a conserved catabolic pathway that is vital for maintaining
cell homeostasis and promoting cell survival under stressful conditions. Dysregulation of …

The role of glial autophagy in Alzheimer's disease

A Litwiniuk, GR Juszczak, AM Stankiewicz… - Molecular …, 2023 - nature.com
Although Alzheimer's disease is the most pervasive neurodegenerative disorder, the
mechanism underlying its development is still not precisely understood. Available data …

Lysosomes in senescence and aging

JX Tan, T Finkel - EMBO reports, 2023 - embopress.org
Dysfunction of lysosomes, the primary hydrolytic organelles in animal cells, is frequently
associated with aging and age‐related diseases. At the cellular level, lysosomal dysfunction …

Preclinical models for Alzheimer's disease: past, present, and future approaches

A Akhtar, SM Gupta, S Dwivedi, D Kumar… - ACS …, 2022 - ACS Publications
A robust preclinical disease model is a primary requirement to understand the underlying
mechanisms, signaling pathways, and drug screening for human diseases. Although various …

Pyrazoline containing compounds as therapeutic targets for neurodegenerative disorders

MJ Ahsan, A Ali, A Ali, A Thiriveedhi, MA Bakht… - ACS …, 2022 - ACS Publications
Pyrazolines are a significant class of heterocyclic compounds with essential biological
activities. They are quite stable, which has inspired medicinal chemists to experiment with …

Nanoparticle cluster depolymerizes and removes amyloid fibrils for Alzheimer's disease treatment

Q Feng, N Wang, X Zhang, Y Mei, R Fu, J Chen… - Nano Today, 2023 - Elsevier
Aberrant amyloid-β (Aβ) fibrillation is the key event in Alzheimer's disease (AD), the
depolymerization and removal of which are being pursued with enthusiasm. Herein, a …

Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease

W Zhang, J Wang, C Yang - Autophagy, 2022 - Taylor & Francis
Alzheimer disease (AD) is the most common neurodegenerative disease. Unfortunately,
current effective therapeutics for AD are limited and thus the discovery of novel anti-AD …